Τίτλος:
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Chemoimmunotherapy is typically the standard of care for patients with Waldenström macroglobulinemia; however, infectious and hematologic toxic effects are problematic. Acalabrutinib is a selective, potent Bruton tyrosine-kinase inhibitor. The aim of this trial was to evaluate the activity and safety of acalabrutinib in patients with Waldenström macroglobulinemia. Methods: This single-arm, multicentre, phase 2 trial was done in 19 European academic centres in France, Italy, Greece, the Netherlands, and the UK, and eight academic centres in the USA. Eligible patients were 18 years or older and had treatment naive (declined or not eligible for chemoimmunotherapy) or relapsed or refractory (at least one previous therapy) Waldenström macroglobulinemia that required treatment, an Eastern Cooperative Oncology Group performance status of 2 or less, and received no previous Bruton tyrosine-kinase inhibitor therapy. Patients received 100 mg oral acalabrutinib twice per day in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed overall response (at least a minor response) according to the 6th International Workshop for Waldenström Macroglobulinemia (IWWM) and the modified 3rd IWWM workshop criteria. The primary outcome and safety were assessed in all patients who received at least one dose of treatment. This study is registered with ClinicalTrials.gov, number NCT02180724, and is ongoing, but no longer enrolling. Findings: Between Sept 8, 2014, and Dec 24, 2015, 122 patients were assessed for eligibility, of which 106 (87%) patients were given acalabrutinib (14 were treatment naive and 92 had relapsed or refractory disease). With a median follow-up of 27·4 months (IQR 26·0–29·7), 13 (93% [95% CI 66–100]) of 14 treatment naive patients achieved an overall response and 86 (93% [86–98]) of 92 relapsed or refractory patients per both the modified 3rd and 6th IWWM criteria. Seven (50%) of 14 treatment naive patients and 23 (25%) of 92 relapsed or refractory patients discontinued treatment on study. Grade 3–4 adverse events occurring in more than 5% of patients were neutropenia (17 [16%] of 106 patients) and pneumonia (7 [7%]). Grade 3–4 atrial fibrillation occurred in one (1%) patient and grade 3–4 bleeding occurred in three (3%) patients. The most common serious adverse events were lower respiratory tract infection (n=7 [7%]), pneumonia (n=7 [7%]), pyrexia (n=4 [4%]), cellulitis (n=3 [3%]), fall (n=3 [3%]), and sepsis (n=3 [3%]). Pneumonia (n=5 [5%]) and lower respiratory tract infection (n=4 [4%]) were considered treatment related. One treatment-related death was reported (intracranial hematoma). Interpretation: This study provides evidence that acalabrutinib is active as single-agent therapy with a manageable safety profile in patients with treatment-naive, or relapse or refractory Waldenström macroglobulinemia. Further studies are needed to establish its efficacy against current standard treatments and to investigate whether outcomes can be improved with combination therapies. Funding: Acerta Pharma. © 2020 Elsevier Ltd
Συγγραφείς:
Owen, R.G.
McCarthy, H.
Rule, S.
D'Sa, S.
Thomas, S.K.
Tournilhac, O.
Forconi, F.
Kersten, M.J.
Zinzani, P.L.
Iyengar, S.
Kothari, J.
Minnema, M.C.
Kastritis, E.
Aurran-Schleinitz, T.
Cheson, B.D.
Walter, H.
Greenwald, D.
Chen, D.-Y.
Frigault, M.M.
Hamdy, A.
Izumi, R.
Patel, P.
Wei, H.
Lee, S.K.
Mittag, D.
Furman, R.R.
Περιοδικό:
The Lancet Haematology
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
acalabrutinib; alanine aminotransferase; antifungal agent; bendamustine; Bruton tyrosine kinase; chemokine receptor CXCR4; chlorambucil; cisplatin; cyclophosphamide; cytarabine; dexamethasone; doxorubicin; myeloid differentiation factor 88; prednisone; proteasome inhibitor; purine derivative; rituximab; vincristine; acalabrutinib; antineoplastic agent; benzamide derivative; BTK protein, human; MYD88 protein, human; myeloid differentiation factor 88; protein kinase inhibitor; pyrazine derivative; tumor protein, abdominal pain; acute kidney failure; acute pancreatitis; adult; aged; anemia; arthralgia; Article; ascites; aspergillosis; asthenia; atrial fibrillation; B lymphocyte; backache; basal cell carcinoma; bleeding; blood viscosity; bone marrow biopsy; brain hematoma; bronchiectasis; cancer survival; cellulitis; cerebrovascular accident; chronic obstructive lung disease; compression fracture; constipation; contusion; coronary artery disease; coughing; Crohn disease; decreased appetite; diarrhea; disease exacerbation; dizziness; drug safety; drug withdrawal; dyspepsia; dyspnea; empyema; enzyme linked immunosorbent assay; epiglottitis; epistaxis; erythema; Escherichia coli infection; esophagus carcinoma; faintness; fatigue; febrile neutropenia; female; femoral neck fracture; fever; flow cytometry; follow up; France; gastroenteritis; glioblastoma; Greece; head injury; headache; heart muscle ischemia; hip fracture; human; human tissue; hypertension; hyponatremia; hypotension; influenza; Italy; joint dislocation; lower respiratory tract infection; lung infection; major clinical study; male; malignant ascites; metastatic melanoma; metrorrhagia; migraine; monotherapy; multicenter study; natural killer cell; nausea; Netherlands; neutropenia; orthostatic hypotension; outcome assessment; overall survival; phase 2 clinical trial; phrenic nerve paralysis; pneumonia; presyncope; progression free survival; prospective study; prostate cancer; prostate hypertrophy; prostatitis; rash; retina detachment; retina hemorrhage; Rhinovirus infection; rib fracture; Rotavirus infection; Sanger sequencing; seizure; sepsis; septic shock; side effect; sinusitis; skin abscess; skin defect; spine fracture; stomach ulcer; stomatitis; streptococcal pharyngitis; T lymphocyte; tendon rupture; thorax pain; thrombocytopenia; tongue carcinoma; United Kingdom; upper respiratory tract infection; urinary tract infection; urosepsis; vasculitis; viral upper respiratory tract infection; vomiting; Waldenstroem macroglobulinemia; clinical trial; enzymology; gastrointestinal disease; genetics; middle aged; molecularly targeted therapy; neutropenia; pain; quality of life; recurrent disease; respiratory tract infection; salvage therapy; treatment outcome; Waldenstroem macroglobulinemia, Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Neoplasm Proteins; Neutropenia; Pain; Protein Kinase Inhibitors; Pyrazines; Quality of Life; Recurrence; Respiratory Tract Infections; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia
DOI:
10.1016/S2352-3026(19)30210-8
